Omnicell, Inc. (NASDAQ:OMCL) reported better-than-expected earnings and revenue for the second quarter on Thursday, fueled by strong demand for its point-of-care connected devices. Following the release, the pharmacy automation company’s shares rose 2.76% in pre-market trading.
The company posted adjusted earnings of $0.45 per share for Q2, well above the analyst consensus of $0.27. Revenue reached $290.56 million, beating estimates of $275.28 million and marking a 5% increase from the same quarter last year.
“We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided guidance,” said Randall Lipps, chairman, president, CEO, and founder of Omnicell.
Omnicell noted particular strength in its point-of-care connected devices, including the XT Series automated dispensing cabinets and the XTExtend console. Additional contributions came from technical services, SaaS and Expert Services, and consumables revenues.
Looking ahead, Omnicell forecasts third-quarter revenue between $290 million and $300 million, above the consensus estimate of $284.1 million. Adjusted earnings per share are expected between $0.30 and $0.37, slightly below analysts’ estimate of $0.37.
The company also raised its full-year 2025 guidance, now projecting revenue between $1.13 billion and $1.16 billion, and adjusted earnings per share ranging from $1.40 to $1.65, compared with the analyst consensus of $1.37.
Omnicell reported GAAP net income of $6 million, or $0.12 per diluted share, up from $4 million, or $0.08 per share, in the second quarter of 2024. The company closed the quarter with $399 million in cash and cash equivalents and total debt of $342 million.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.